An observational study in Prostatectomy, Cystectomy and Nephrectomy, sponsored by Medtronic - MITG. Not yet recruiting. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Medtronic - MITG (part of Medtronic) · Observational
The purpose of this study is to collect evidence on the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.
This study's planned enrollment of 110 is below the median of 174 across 33 observational studies indexed under Urologic Neoplasms.
Browse Urologic Neoplasms studies →Medtronic - MITG is the lead sponsor of 179 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
The Medtronic Hugo™ RAS System is intended to be used in this study for urologic surgical procedures including radical prostatectomy, radical cystectomy, nephrectomy (partial/radical). Subject conditions and/or diagnoses may include but are not limited to: prostate cancer, pelvic tumors, interstitial cystitis, congenital abnormalities, end-stage kidney disease (kidney failure), renal tumor, and kidney injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Medtronic Hugo™ RAS System is intended to be used in this study for urologic surgical procedures including radical prostatectomy, radical cystectomy, nephrectomy (partial/radical) procedures
Surgical Success Rate
Surgical success rate, defined as a Hugo™ RAS procedure free from conversion. A qualifying conversion is an unanticipated switch from a robotic-assisted approach using the Hugo™ RAS System to the use of an alternative robotic-assisted device, laparoscopy, or open surgery.
Time frame: Intraoperative
Rate of Complications
Rate of subjects with complications meeting Clavien-Dindo Grade ≥ III from first incision through 30 days postprocedure
Time frame: Enrollment through 30 days follow-up
Operative Time
Skin-to-skin operative time
Time frame: Intraoperative
Hospital Length of Stay
Total time of hospitalization
Time frame: Postoperatively through 30 days follow-up
Mortality
30 Day Mortality Rate
Time frame: Enrollment through 30 day follow-up
No study locations are listed for this record.
Start is estimated for Feb 2027; primary completion for Apr 2028, 14 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.